- Home
- DSP vs CERS Comparison
DSP vs CERS Comparison
Compare DSP & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- CERS
- Stock Information
- Founded
- DSP 1999
- CERS 1991
- Country
- DSP United States
- CERS United States
- Employees
- DSP N/A
- CERS N/A
- Industry
- DSP EDP Services
- CERS EDP Services
- Sector
- DSP Technology
- CERS Technology
- Exchange
- DSP Nasdaq
- CERS Nasdaq
- Market Cap
- DSP 291.3M
- CERS 347.3M
- IPO Year
- DSP 2021
- CERS 1997
- Fundamental
- Price
- DSP $14.12
- CERS $1.29
- Analyst Decision
- DSP Strong Buy
- CERS Strong Buy
- Analyst Count
- DSP 8
- CERS 2
- Target Price
- DSP $21.75
- CERS $3.50
- AVG Volume (30 Days)
- DSP 263.8K
- CERS 991.7K
- Earning Date
- DSP 05-06-2025
- CERS 05-01-2025
- Dividend Yield
- DSP N/A
- CERS N/A
- EPS Growth
- DSP N/A
- CERS N/A
- EPS
- DSP 0.13
- CERS N/A
- Revenue
- DSP $306,484,000.00
- CERS $185,144,000.00
- Revenue This Year
- DSP $19.25
- CERS $25.57
- Revenue Next Year
- DSP $16.72
- CERS $10.54
- P/E Ratio
- DSP $109.37
- CERS N/A
- Revenue Growth
- DSP 30.64
- CERS 13.06
- 52 Week Low
- DSP $8.62
- CERS $1.12
- 52 Week High
- DSP $26.33
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- DSP 55.48
- CERS 45.00
- Support Level
- DSP $12.58
- CERS $1.22
- Resistance Level
- DSP $15.31
- CERS $1.38
- Average True Range (ATR)
- DSP 0.80
- CERS 0.07
- MACD
- DSP 0.15
- CERS 0.00
- Stochastic Oscillator
- DSP 81.76
- CERS 26.92
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.